

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

beta 2 Microglobulin antibody [EP2978Y]

RRID:AB_1523204

Type: Antibody

Proper Citation

Abcam Cat# ab75853, RRID:AB_1523204

Antibody Information

URL: http://antibodyregistry.org/AB_1523204

Proper Citation: Abcam Cat# ab75853, RRID:AB_1523204

Target Antigen: beta 2 Microglobulin antibody [EP2978Y]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Flow Cyt, ICC, IP, WB; Immunocytochemistry; Immunoprecipitation; Flow Cytometry; Western Blot

Antibody Name: beta 2 Microglobulin antibody [EP2978Y]

Description: This monoclonal targets beta 2 Microglobulin antibody [EP2978Y]

Target Organism: rat, mouse, human

Antibody ID: AB_1523204

Vendor: Abcam

Catalog Number: ab75853

Record Creation Time: 20250819T232520+0000

Record Last Update: 20250820T051730+0000

Ratings and Alerts

No rating or validation information has been found for beta 2 Microglobulin antibody [EP2978Y].

No alerts have been found for beta 2 Microglobulin antibody [EP2978Y].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tang D, et al. (2025) Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. *Cell reports. Medicine*, 6(7), 102211.

Thapa R, et al. (2025) Single-nucleus RNA sequencing reveals GABAergic vulnerability and reactive gliosis driven by loss of TDP-43. *iScience*, 28(11), 113745.

Mahauad-Fernandez WD, et al. (2025) Targeting the MYC oncogene with a selective bis-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers. *Cell chemical biology*, 32(8), 994.

Gao Y, et al. (2023) β 2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function. *Cell*, 186(5), 1026.

Chen X, et al. (2023) A membrane-associated MHC-I inhibitory axis for cancer immune evasion. *Cell*, 186(18), 3903.

Zhang Z, et al. (2022) A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. *Cancer cell*, 40(9), 1060.

Xiong X, et al. (2022) Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. *Cell*, 185(7), 1157.

Margolis N, et al. (2022) Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. *Cancer immunology research*, 10(9), 1127.

Parmigiani E, et al. (2022) Interferon- γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. *Developmental cell*, 57(15), 1847.

Hofbauer D, et al. (2021) β 2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. *Immunity*, 54(8), 1772.

Bevington SL, et al. (2020) Chromatin Priming Renders T Cell Tolerance-Associated Genes Sensitive to Activation below the Signaling Threshold for Immune Response Genes. *Cell reports*, 31(10), 107748.

Meoli L, et al. (2019) Intestine-Specific Overexpression of LDLR Enhances Cholesterol Excretion and Induces Metabolic Changes in Male Mice. *Endocrinology*, 160(4), 744.

Ben-Zvi D, et al. (2018) Time-Dependent Molecular Responses Differ between Gastric Bypass and Dieting but Are Conserved Across Species. *Cell metabolism*, 28(2), 310.